Annovis Bio to Attend a Major Investment Conference
MALVERN, Pa. — Annovis Bio Inc. (NYSE: ANVS), an innovative company dedicated to creating advanced therapies for neurodegenerative diseases, is gearing up for the H.C. Wainwright 26th Annual Global Investment Conference. The company is eager to showcase its latest advancements in clinical development and its strategic vision, emphasizing its commitment to innovation.
Details of the Conference and Presentations
The conference is set to occur from September 9-11, 2024, both virtually and in person at the esteemed Lotte New York Palace Hotel. Annovis Bio's CEO, Maria L. Maccecchini, Ph.D., will deliver a presentation on September 10 at 8:00 a.m. Eastern Time. This session will offer investors and attendees valuable insights into the company's efforts to address the challenges posed by neurodegeneration.
Panel Discussion on Alzheimer’s Strategies
Alongside her presentation, Dr. Maccecchini will participate in a panel discussion on the same day at 2:00 p.m. This discussion, titled "Non-amyloid Approaches in Alzheimer’s Disease," will feature prominent representatives from Annovis Bio as well as other forward-thinking companies. This panel provides Annovis with a platform to highlight its distinctive strategies for tackling Alzheimer’s disease in collaboration with industry peers.
Commitment to Innovation in Neurodegenerative Diseases
Annovis Bio is focused on developing solutions for neurodegenerative diseases, including Alzheimer's disease (AD) and Parkinson’s disease (PD). The company utilizes a unique approach that targets multiple neurotoxic proteins, aiming to restore cognitive function and improve the quality of life for patients. With a proactive research and development strategy, Annovis is leading the charge in addressing the complexities of these challenging conditions.
Opportunities for Investor Engagement
For investors looking to connect directly with the company's leadership, Annovis is facilitating one-on-one meetings with Dr. Maccecchini. Attendees can arrange these meetings through the conference portal, presenting a valuable opportunity to discuss the company's innovative pipeline and strategic direction in more detail.
About Annovis Bio, Inc.
Based in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated to overcoming the hurdles of neurodegeneration through its innovative drug development platform. By concentrating on new treatment methods, the company aims to revolutionize the available therapies for patients dealing with neurodegenerative diseases.
Contact Information
Office of Annovis Bio:
101 Lindenwood Drive, Suite 225
Malvern, PA 19355
Website: www.annovisbio.com
Investor Contact:
Scott McGowan
InvestorBrandNetwork (IBN)
Phone: 310.299.1717
Email: IR@annovisbio.com
Frequently Asked Questions
What is Annovis Bio focusing on at the conference?
Annovis Bio will highlight its recent developments and strategies for addressing neurodegenerative diseases, particularly Alzheimer's and Parkinson's.
When is Annovis Bio's presentation scheduled?
The presentation is set for September 10, 2024, from 8:00 to 8:30 a.m. Eastern Time.
Who will be participating in the panel discussion?
Dr. Maria L. Maccecchini will represent Annovis, along with representatives from Anavex Life Sciences Corp. and Longeveron Inc.
How can investors meet with Annovis Bio's CEO?
Investors can arrange one-on-one meetings through the conference portal during the event.
What is Annovis Bio's mission?
Annovis Bio is dedicated to developing innovative therapies that target the root causes of neurodegeneration, with the goal of enhancing patient outcomes and quality of life.
